Figure 1
Kaplan-Meier analysis of the time to developing hematologic and clinical outcome events in PMF patients according to their JAK2V617F mutational status. The plots show time to anemia (hemoglobin < 100 g/L), leukopenia (leukocytes < 4 × 109/L), leukocytosis (> 25 × 109/L), thrombocytopenia (< 100 × 109/L), large splenomegaly (> 15 cm from left costal margin in patients presenting smaller spleen at diagnosis), and time to leukemic transformation. P values are shown inside each box. WT indicates JAK2 wild-type patients; V617F, JAK2V617F mutated patients.

Kaplan-Meier analysis of the time to developing hematologic and clinical outcome events in PMF patients according to their JAK2V617F mutational status. The plots show time to anemia (hemoglobin < 100 g/L), leukopenia (leukocytes < 4 × 109/L), leukocytosis (> 25 × 109/L), thrombocytopenia (< 100 × 109/L), large splenomegaly (> 15 cm from left costal margin in patients presenting smaller spleen at diagnosis), and time to leukemic transformation. P values are shown inside each box. WT indicates JAK2 wild-type patients; V617F, JAK2V617F mutated patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal